financetom
Business
financetom
/
Business
/
Dubai's Emirates NBD partners with BlackRock to offer private markets access
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dubai's Emirates NBD partners with BlackRock to offer private markets access
Mar 25, 2025 6:26 AM

DUBAI, March 25 (Reuters) - Dubai's Emirates NBD

bank is teaming up with BlackRock ( BLK ) to offer its

wealth management clients opportunities to access alternative

asset classes, with a focus on private markets, it said in a

statement on Tuesday.

Both firms have signed a Memorandum of Understanding to

establish an investment platform for the United Arab Emirates

(UAE) wealth management market, which will initially focus on

private credit and multi-alternatives.

Private markets, including both equity and credit markets,

are less liquid but also promise higher returns than listed

securities.

Global demand for private market investments has been

growing in recent years, providing investors with opportunities

to diversify their portfolios and seek greater returns, as

global capital markets activity slowed amid higher borrowing

costs.

BlackRock ( BLK ), the world's largest asset manager, spent roughly

$28 billion in 2024 to strengthen its private market offerings.

Emirates NBD Asset Management clients will be able to invest

in private markets through BlackRock's ( BLK ) Alternative Investments

platform, which currently has over $450 billion in assets under

management, according to Tuesday's statement.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nucor Insider Sold Shares Worth $1,449,020, According to a Recent SEC Filing
Nucor Insider Sold Shares Worth $1,449,020, According to a Recent SEC Filing
Aug 20, 2025
10:12 AM EDT, 08/20/2025 (MT Newswires) -- Kenneth Rex Query, Executive Vice President, on August 18, 2025, sold 10,000 shares in Nucor ( NUE ) for $1,449,020. Following the Form 4 filing with the SEC, Query has control over a total of 84,080 common shares of the company, with 84,080 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/73309/000112760225020756/xslF345X05/form4.xml Price: 143.72, Change: -2.19,...
Crypto Exchange Kraken Acquires No-Code Trading Firm Capitalise.ai to Expand Pro Platform
Crypto Exchange Kraken Acquires No-Code Trading Firm Capitalise.ai to Expand Pro Platform
Aug 20, 2025
Crypto ( CRCW ) exchange Kraken has acquired the assets and technology of Capitalise.ai, an Israel-based startup that built a natural-language, no-code platform for automating trading strategies across multiple asset classes, the company said in a press release Wednesday. Keefe, Bruyette & Woods, a Stifel company, acted as financial advisor to Capitalise.ai. Financial details of the acquisition were not disclosed....
Nucor Insider Sold Shares Worth $1,051,200, According to a Recent SEC Filing
Nucor Insider Sold Shares Worth $1,051,200, According to a Recent SEC Filing
Aug 20, 2025
10:11 AM EDT, 08/20/2025 (MT Newswires) -- Daniel R. Needham, Executive Vice President, on August 18, 2025, sold 7,200 shares in Nucor ( NUE ) for $1,051,200. Following the Form 4 filing with the SEC, Needham has control over a total of 92,179 common shares of the company, with 92,179 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/73309/000112760225020757/xslF345X05/form4.xml Price: 143.57, Change: -2.34,...
Keros Therapeutics Gets FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Treatment
Keros Therapeutics Gets FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Treatment
Aug 20, 2025
10:10 AM EDT, 08/20/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Wednesday that KER-065 was granted orphan drug designation by the US Food and Drug Administration for the treatment of Duchenne muscular dystrophy. Keros said it plans to advance the treatment to a phase 2 clinical trial. Price: 14.54, Change: +0.05, Percent Change: +0.35 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved